Page last updated: 2024-08-21

tocopherols and Depression

tocopherols has been researched along with Depression in 3 studies

Research

Studies (3)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's1 (33.33)29.6817
2010's2 (66.67)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Holford, NH; Nutt, JG; Vu, TC2
Maevskii, EI; Peskov, AB; Sakharova, NY; Uchitel', ML; Vize-Khripunova, MA1

Trials

1 trial(s) available for tocopherols and Depression

ArticleYear
Succinate-based preparation alleviates manifestations of the climacteric syndrome in women.
    Bulletin of experimental biology and medicine, 2005, Volume: 140, Issue:3

    Topics: Adult; alpha-Tocopherol; Anxiety; Blood Glucose; Climacteric; Depression; Female; Food Additives; Fumarates; Glutamine; Glycine; Gonadal Steroid Hormones; Hot Flashes; Humans; Lipids; Middle Aged; Sleep Initiation and Maintenance Disorders; Succinates; Tocopherols

2005

Other Studies

2 other study(ies) available for tocopherols and Depression

ArticleYear
Progression of motor and nonmotor features of Parkinson's disease and their response to treatment.
    British journal of clinical pharmacology, 2012, Volume: 74, Issue:2

    Topics: Antiparkinson Agents; Cognition Disorders; Depression; Disability Evaluation; Disease Progression; Drug Substitution; Drug Therapy, Combination; Gait Disorders, Neurologic; Humans; Hypokinesia; Linear Models; Motor Activity; Nonlinear Dynamics; Parkinson Disease; Patient Dropouts; Postural Balance; Predictive Value of Tests; Psychiatric Status Rating Scales; Randomized Controlled Trials as Topic; Retrospective Studies; Selegiline; Sensation Disorders; Severity of Illness Index; Surveys and Questionnaires; Time Factors; Tocopherols; Treatment Outcome; Tremor

2012
Disease progress and response to treatment as predictors of survival, disability, cognitive impairment and depression in Parkinson's disease.
    British journal of clinical pharmacology, 2012, Volume: 74, Issue:2

    Topics: Adult; Aged; Analysis of Variance; Antiparkinson Agents; Chi-Square Distribution; Cognition; Cognition Disorders; Depression; Disability Evaluation; Disease Progression; Humans; Kaplan-Meier Estimate; Middle Aged; Parkinson Disease; Patient Dropouts; Predictive Value of Tests; Psychiatric Status Rating Scales; Randomized Controlled Trials as Topic; Retrospective Studies; Risk Assessment; Risk Factors; Selegiline; Severity of Illness Index; Time Factors; Tocopherols; Treatment Outcome

2012